Literature DB >> 11410717

4-Methylpyrazole decreases salivary acetaldehyde levels in aldh2-deficient subjects but not in subjects with normal aldh2.

S Väkeväinen1, J Tillonen, M Salaspuro.   

Abstract

BACKGROUND: Carcinogenic acetaldehyde is produced from ethanol locally in the upper digestive tract via alcohol dehydrogenases (ADHs) of oral microbes, mucosal cells, and salivary glands. Acetaldehyde is further oxidized into less harmful acetate mainly by the aldehyde dehydrogenase-2 (ALDH2) enzyme. ALDH2-deficiency increases salivary acetaldehyde levels and the risk for upper digestive tract cancer in heavy alcohol drinkers. 4-methylpyrazole (4-MP) is an ADH-inhibitor which could reduce the local production of acetaldehyde from ethanol in the saliva.
METHODS: Five ALDH2-deficient subjects and six subjects with normal ALDH2 ingested a moderate dose of alcohol (0.4 g/kg of body weight), whereafter their salivary acetaldehyde levels, heart rate, skin temperature, and blood pressure were followed for up to four hours. Blood acetaldehyde and ethanol levels were determined at 60 min. The experiment was repeated after a week. Two hours before the second study day, the volunteers received 4-MP, 10-15 mg/kg of body weight orally.
RESULTS: Total ethanol elimination rate decreased with 4-MP by 38-46% in all subjects. 4-MP also reduced blood acetaldehyde levels and suppressed the cardiocirculatory responses of the ALDH2-deficient volunteers. In addition, salivary acetaldehyde production in ALDH2-deficient subjects was significantly reduced when correlated with salivary ethanol levels. On the contrary, 4-MP did not have any effect on salivary or blood acetaldehyde levels in subjects with normal ALDH2.
CONCLUSIONS: A single dose of 4-MP before ethanol ingestion reduces ethanol elimination rate, the flushing reaction, and both blood and salivary acetaldehyde levels in ALDH2-deficient subjects but not in subjects with the normal ALDH2 genotype. These results suggest that the role of oral mucosal and glandular ADHs in salivary acetaldehyde production is minimal and support earlier findings indicating that salivary acetaldehyde production is mainly of microbial origin in subjects with normal ALDH2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410717

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  13 in total

1.  Alcohol Intake and Risk of Incident Melanoma: A Pooled Analysis of Three Prospective Studies in the United States.

Authors:  Andrew Rivera; Hongmei Nan; Tricia Li; Abrar Qureshi; Eunyoung Cho
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12       Impact factor: 4.254

2.  Systemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion.

Authors:  Yuki Matsumura; Na Li; Hanan Alwaseem; Odelya E Pagovich; Ronald G Crystal; Matthew B Greenblatt; Katie M Stiles
Journal:  Hum Gene Ther       Date:  2020-01-28       Impact factor: 5.695

3.  Increased cancer risk in heavy drinkers with the alcohol dehydrogenase 1C*1 allele, possibly due to salivary acetaldehyde.

Authors:  J P Visapää; K Götte; M Benesova; J Li; N Homann; C Conradt; H Inoue; M Tisch; K Hörrmann; S Väkeväinen; M Salaspuro; H K Seitz
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

4.  Multiple alcohol dehydrogenases but no functional acetaldehyde dehydrogenase causing excessive acetaldehyde production from ethanol by oral streptococci.

Authors:  Sylvia I Pavlova; Ling Jin; Stephen R Gasparovich; Lin Tao
Journal:  Microbiology       Date:  2013-05-01       Impact factor: 2.777

5.  Short-term salivary acetaldehyde increase due to direct exposure to alcoholic beverages as an additional cancer risk factor beyond ethanol metabolism.

Authors:  Dirk W Lachenmeier; Yulia B Monakhova
Journal:  J Exp Clin Cancer Res       Date:  2011-01-06

Review 6.  Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.

Authors:  Rachel A Montel; Carlos Munoz-Zuluaga; Katie M Stiles; Ronald G Crystal
Journal:  Cancer Gene Ther       Date:  2021-11-19       Impact factor: 5.854

7.  Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intragastric alcohol administration.

Authors:  Ryuhei Maejima; Katsunori Iijima; Pertti Kaihovaara; Waku Hatta; Tomoyuki Koike; Akira Imatani; Tooru Shimosegawa; Mikko Salaspuro
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

8.  ALDH2 genotype has no effect on salivary acetaldehyde without the presence of ethanol in the systemic circulation.

Authors:  Andreas Helminen; Satu Väkeväinen; Mikko Salaspuro
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

Review 9.  Local Acetaldehyde: Its Key Role in Alcohol-Related Oropharyngeal Cancer.

Authors:  Mikko Salaspuro
Journal:  Visc Med       Date:  2020-05-12

Review 10.  Ethanol versus Phytochemicals in Wine: Oral Cancer Risk in a Light Drinking Perspective.

Authors:  Elena M Varoni; Giovanni Lodi; Marcello Iriti
Journal:  Int J Mol Sci       Date:  2015-07-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.